WEST TISBURY, Massachusetts
Radikal Therapeutics today announced that the Company has been joined by Dr. Garry J. Southan, who will assume the position of Vice-President of Research. A synthetic chemist by training, Dr. Southan has an extensive experience and publication record in nitric oxide synthase (NOS) and in the chemistry of NOS inhibitors, nitric oxide (NO) adducts, and NO donor compounds. He has spent 3 years with the Nobel Laureate Sir John R. Vane, FRS at the William Harvey Research Institute in London, England to study the biochemistry of NO and NO synthases. Dr. Southan also served at the National Cancer Institute in the laboratory of Larry Keefer, a leading group in the development of novel NO adducts. Dr. Southan has successfully identified, synthesized, and characterized a wide variety of novel NOS inhibitors as well as NO donor compounds. He has developed or refined and used all relevant experimental techniques in the present application. Dr. Southan is the author of invited reviews and an invited speaker at international meetings on the topic of NOS inhibitors. He is involved in studies on the biochemistry of NO and NO donors, and continues his effort in order to develop NOS inhibitors.
Prior to joining Radikal Therapeutics, Dr. Southan served for 12 years as Founder and Executive Vice-President of Chemistry at Inotek Pharmaceuticals Corporation. In that capacity, he led numerous pharmaceutical projects based on new chemical entities invented by his group, from the point of discovery into Phase 2 clinical trials. As a supervisor of 70 chemists and support personnel, and the leader of a GMP manufacturing facility and quality control laboratories, Dr. Southan had broad experience in the pharmaceutical development process.
In his current role as Vice-President of Research, Dr. Southan will lead a group of senior chemists, biologists, and pharmacologists to identify, discover, in-license, and develop innovative life science technologies.
About Radikal Therapeutics (RTX)
RTX is a multi-national biotechnology firm focused on the discovery and development of transformative pharmaceuticals. With a deep pipeline of therapeutics created in-house, and a paradigm-disruptive discovery engine, the Company is positioned to remain at the forefront of drug discovery. RTX’s team of chemists, biologists, immunologists, and drug development professionals has worked together for more than two decades and has built a reputation for leadership in basic science and drug development. The Company is developing best-in-class therapeutics in a range of clinical areas, including inflammation, ischemia-reperfusion injury, and auto-immunity. The product platforms include small and large molecule pharmaceuticals that therapeutically restore free radical equilibrium, redirect aberrant signaling pathways in inflammation, manipulate mitochondrial cell death pathways, modulate DNA repair, restore microcirculatory perfusion, and induce specific immunotolerance. Although varied in their structural targets and directed at diverse clinical needs, the Company’s technologies share a unified concept of correcting pathophysiology by endowing agents with multi-functional capacity. This approach yields biological synergies that far outstrip the potency of traditional single-target agents.
Via its sister firm Luria Scientific Industries (LSI), RTX makes available its deep and unique experience in pre-clinical and clinical development for the benefit of the biotech and pharmaceutical industry.
Andrew L. Salzman, M.D.